Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
Elena Spínola-Lasso, Juan Carlos Montero, Roberto Jiménez‐Monzón, Francisco Estévez, José M. Quintana, Borja Guerra, Khaled M. Elokely, Francisco León, Henoc del Rosario, Leandro Fernández‐Pérez, Manuel Rodríguez López, B.N. Díaz-Chico, Grant McNaughton‐Smith, Atanasio Pandiella, JC Diaz-Chico
Abstract
/M phases, and the activation of caspase-dependent apoptosis. Taken together, our results identify a novel compound with antitumoral properties against TNBC. In addition, we describe the mechanism of action of this drug and provide a rationale for the use of Prdx1 inhibitors, such as CM728, alone or in combination with other drugs, for the treatment of TNBC.
Topics & Concepts
Triple-negative breast cancerCancer researchDownregulation and upregulationApoptosisChemistryMAPK/ERK pathwayDNA damagep38 mitogen-activated protein kinasesIn vivoPharmacologyCancerBreast cancerSignal transductionBiologyBiochemistryDNAGeneBiotechnologyGeneticsRedox biology and oxidative stressSynthesis and biological activityBioactive Compounds and Antitumor Agents